Drugs / ICAR30 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03383965 | Mar 2017 → Dec 2020 | Hodgkins lymphoma, anaplastic large cell lymphoma | Immune Cell, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICAR30 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383965 ↗ |
| Action | Deplete | “specifically kill those CD30 expressing malignancies” NCT03383965 ↗ |
| Modality | Cell therapy | “anti-CD30 CAR-T cells” NCT03383965 ↗ |
| Route | Intravenous | “infused into the patients by IV” NCT03383965 ↗ |